74465-19-3

Usage

Uses

Used in Chemical Industry:
(2R,3S,5S,6S)-2,3,5,6-tetrahydroxycyclohexane-1,4-diyl bis[dihydrogen (phosphate)] is used as a building block for synthesizing various complex organic molecules and pharmaceutical compounds due to its unique cyclohexane core and reactive hydroxyl and phosphate groups.
Used in Pharmaceutical Industry:
(2R,3S,5S,6S)-2,3,5,6-tetrahydroxycyclohexane-1,4-diyl bis[dihydrogen (phosphate)] is used as a potential therapeutic agent for the development of drugs targeting specific biological pathways and receptors, given its high water solubility and unique structure that can be modified for specific interactions.
Used in Biotechnology Industry:
(2R,3S,5S,6S)-2,3,5,6-tetrahydroxycyclohexane-1,4-diyl bis[dihydrogen (phosphate)] is used as a component in the design of novel biomaterials and drug delivery systems, taking advantage of its water solubility and ability to form stable complexes with other molecules.
Used in Environmental Applications:
(2R,3S,5S,6S)-2,3,5,6-tetrahydroxycyclohexane-1,4-diyl bis[dihydrogen (phosphate)] is used as a component in the development of eco-friendly chemicals and materials, such as biodegradable plastics and water treatment agents, due to its biodegradable nature and potential to form complexes with pollutants.

Upstream product

• 87-89-8 D-myo-inositol 
• 75194-94-4 3,3,7,7-tetramethyl-2,8-dioxa-5-aza-1λ³-phosphabicyclo(3,3,0)octane 
• 138480-27-0 D-1,4-di-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)-2,3-O-(D-1,7,7-trimethyl<2.2.1>bicyclohept-2-ylidene)-5,6-O-isopropylidene-myo-inositol 
• 37170-02-8 (+)-2,3:5,6-(1,2:4,5)-dicyclohexylidene-myo-inositol 1,4-(3,6)-bis(diphenylphosphate) 
• 222420-78-2 (1R,2S,3S,4R)-1,4-bis-O-(di-O-benzylphospho)conduritol B 
• 34361-60-9 1,2:4,5-dicyclohexylidene-myo-inositol 
• 117666-29-2 (+/-)-3,6-di-O-allyl-4-O-benzyl-1,2-O-cyclohexylidene-myo-inositol 
• 136740-88-0 (+/-)-2,3,6-tri-O-benzyl-myo-inositol 1,4-bis(dibenzyl phosphate) 
• 34361-60-9 1L-1,2:4,5-di-O-cyclohexylidene-myo-inositol 
• 138480-24-7 D-1,4-di-O-tert-butyldimethylsilyl-2,3-O-(D-1,7,7-trimethyl<2.2.1>-bicyclohept-2-ylidene)-myo-inositol 
• 138480-26-9 D-5,6-O-isopropylidene-2,3-O-(D-1,7,7-trimethyl<2.2.1>bicyclohept-2-ylidene)-myo-inositol 
• 128459-27-8 1D-2,3-O-(D-1',7',7'-trimethyl<2.2.1>bicyclohept-2'-ylidene)-myo-inositol 
• 112204-05-4 (+/-)-3,6-di-O-allyl-1,2-O-cyclohexylidene-myo-inositol 
• 51548-88-0 (+/-)-1,2:4,5-di-O-isopropylidene-myo-inositol 

Relevant academic research and scientific papers

A Chiral Phosphoramidite Reagent for the Synthesis of Inositol Phosphates

There is a paucity of chiral phosphoramidite reagents or chiral catalysis methods for the synthesis of biologically relevant inositol phosphates. A new C2-symmetrical chiral phosphoramidite has been developed and successfully applied to the syn

Flexible stereo- and regioselective synthesis of myo-inositol phosphates (part 1): Via symmetrical conduritol B derivatives

A practical route is described for the preparation of myo-inositol polyphosphates. Optically pure myo-inositol derivatives can be prepared from p-benzoquinone in both forms by enzymatic resolution of a C2- symmetric diacetoxyconduritol B key in

A thiophosphate analog of dimyristoylphosphatidyl-inositol-4-phosphate is a substrate for mammalian phosphoinositide-specific phospholipase C

1,2-Dimyristoyloxypropane-3-thiophosphate(rac-1-myo-inositol-4- phosphate), a thiophosphate analog of dimyristoyl phosphatidylinositol-4- phosphate was synthesized as a substrate for mammalian phosphoinositide- specific phospholipase C. Its activity with A(1-132)-PI-PLC-δ1 (a deletion mutant with the N-terminal pleckstrin homology domain removed) was studied in sonicated dispersions, with and without added Triton X-100. It had an initial activity of about 30 μmol min-1 mg-1, which rapidly decreased due to substrate depletion in the vesicle or micelle. The slower rate of hydrolysis appeared limited by enzyme hopping or exchange of substrate between vesicles or micelles, which was more rapid in the presence of detergent.

myo-Inositol 1,4,5-Triphosphate and Related Compounds' Protonation Sequence: Potentiometric and 31P NMR Studies

The protonation sequence of myo-inositol 1,4,5-triphosphate 3>, of its dehydroxylated analogue, Cyhx(1,2,4)P3, of two diphosphorylated inositol phosphates, Ins(1,4)P2 and Ins(4,5)P2 and of one inosit

The synthesis of homochiral inositol phosphates from myo-inositol

A new synthetic procedure for efficient conversion of myo-inositol into homochiral inositol phosphates is presented, and is illustrated with total synthesis of myo-inositol 1-phosphate, 2-deoxy-myo-inositol 1-phosphate, myo-inositol 3-phosphate, myo-inosi

Expedient Synthesis of D-myo-Inositol 1,4,5-Trisphosphate and D-myo-Inositol 1,4-Bisphosphate

Readily available selfresolving myo-inositol D-camphor 2,3-monoacetal is converted into the title inositol phosphates by the concise procedures utilizing 1,4,5-selective tris-acylation and 1,4-selective bis-silylation of the starting tetrol in the key ste

Synthesis of 5-phosphonate analogues of myo-inositol 1,4,5-trisphosphate: Possible intracellular calcium antagonists

The racemic 5-phosphonate analogues IV and V of myo-inositol 1,4,5-trisphosphate were readily accessible by bisphosphorylation of the common precursor 6, removal of the p-methoxybenzyl group, phosphonylation and subsequent hydrogenolysis of the benzyl protecting groups. The methylphosphonate analogue IV acted as a calcium antagonist in permeabilized human platelets, whereas the (difluoromethyl)phosphonate V exhibited only very little antagonistic activity.

THE TOTAL SYNTHESIS OF myo-INOSITOL POLYPHOSPHATES

Total synthesis of the individual enentiomers of myo-inositol 4-phosphate (15), myo-inositol 1,4-biphosphate (2) and myo-inositol 1,4,5-triphosphate (1), together with syntheses of racemic myo-inositol 1,3,4-triphosphate (4) and myo-inositol 2,4,5-triphos